Articles with public access mandates - Mani MahadevanLearn more
Not available anywhere: 1
Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats
CM Dhaenens, S Schraen-Maschke, H Tran, V Vingtdeux, D Ghanem, ...
Experimental neurology 210 (2), 467-478, 2008
Mandates: US National Institutes of Health, National Institute of Health and Medical …
Available somewhere: 15
The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing
A Ravel-Chapuis, G Bélanger, RS Yadava, MS Mahadevan, ...
Journal of Cell Biology 196 (6), 699-712, 2012
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
Therapeutics development in myotonic dystrophy type 1
EP Foff, MS Mahadevan
Muscle & nerve 44 (2), 160-169, 2011
Mandates: US National Institutes of Health
TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy
RS Yadava, EP Foff, Q Yu, JT Gladman, YK Kim, KS Bhatt, CA Thornton, ...
Human molecular genetics 24 (7), 2035-2048, 2015
Mandates: US National Institutes of Health
Evaluating the effects of CELF1 deficiency in a mouse model of RNA toxicity
YK Kim, M Mandal, RS Yadava, L Paillard, MS Mahadevan
Human molecular genetics 23 (2), 293-302, 2014
Mandates: US National Institutes of Health
Myotonic dystrophy: is a narrow focus obscuring the rest of the field?
MS Mahadevan
Current opinion in neurology 25 (5), 609-613, 2012
Mandates: US National Institutes of Health
Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3′UTR RNA
RS Yadava, Q Yu, M Mandal, F Rigo, CF Bennett, MS Mahadevan
Human molecular genetics 29 (9), 1440-1453, 2020
Mandates: US National Institutes of Health
MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity
RS Yadava, YK Kim, M Mandal, K Mahadevan, JT Gladman, Q Yu, ...
Human molecular genetics 28 (14), 2330-2338, 2019
Mandates: US National Institutes of Health
Development of an AP-FRET based analysis for characterizing RNA-protein interactions in myotonic dystrophy (DM1)
S Rehman, JT Gladman, A Periasamy, Y Sun, MS Mahadevan
PloS one 9 (4), e95957, 2014
Mandates: US National Institutes of Health
Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1)
JT Gladman, M Mandal, V Srinivasan, MS Mahadevan
PLoS One 8 (9), e72907, 2013
Mandates: US National Institutes of Health
Cardiac pathology in myotonic dystrophy type 1
MS Mahadevan, RS Yadava, M Mandal
International journal of molecular sciences 22 (21), 11874, 2021
Mandates: US National Institutes of Health
NKX2-5, a modifier of skeletal muscle pathology due to RNA toxicity
JT Gladman, RS Yadava, M Mandal, Q Yu, YK Kim, MS Mahadevan
Human molecular genetics 24 (1), 251-264, 2015
Mandates: US National Institutes of Health
Modeling muscle regeneration in RNA toxicity mice
RS Yadava, M Mandal, JM Giese, F Rigo, CF Bennett, MS Mahadevan
Human Molecular Genetics 30 (12), 1111-1130, 2021
Mandates: US National Institutes of Health
TWEAK regulates muscle functions in a mouse model of RNA toxicity
RS Yadava, EP Foff, Q Yu, JT Gladman, TS Zheng, MS Mahadevan
PLoS One 11 (2), e0150192, 2016
Mandates: US National Institutes of Health
Disease phenotypes in a mouse model of RNA toxicity are independent of protein kinase Cα and protein kinase Cβ
YK Kim, RS Yadava, M Mandal, K Mahadevan, Q Yu, M Leitges, ...
PLoS One 11 (9), e0163325, 2016
Mandates: US National Institutes of Health
Detecting RNA–protein interactions with EGFP‐cy3 FRET by acceptor photobleaching
SR Alam, MS Mahadevan, A Periasamy
Current Protocols 3 (2), e689, 2023
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program